Delcath Systems (NASDAQ:DCTH – Get Free Report) will likely be posting its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $26.00 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.
Delcath Systems (NASDAQ:DCTH – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.16. The company had revenue of $29.13 million during the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. On average, analysts expect Delcath Systems to post ($0.17) EPS for the current fiscal year and $0.12 EPS for the next fiscal year.
Delcath Systems Trading Up 0.6%
NASDAQ DCTH opened at $14.51 on Tuesday. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $17.42. The company has a 50 day moving average of $15.85 and a 200-day moving average of $12.25. The firm has a market cap of $503.50 million, a price-to-earnings ratio of 1,452.45 and a beta of 0.60.
Analysts Set New Price Targets
Several brokerages have recently commented on DCTH. Zacks Research cut Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. BTIG Research lifted their price target on Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Delcath Systems from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, October 13th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target (up from $30.00) on shares of Delcath Systems in a research report on Friday, August 7th. Finally, Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.50.
Read Our Latest Stock Analysis on DCTH
About Delcath Systems
Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.
Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.
Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.
Further Reading
- Five stocks we like better than Delcath Systems
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
